

July 30, 2025

To The Secretary, Listing Department, BSE Limited, 1 <sup>st</sup> Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001.  Scrip Code: <b>540975</b>	To The Manager, Listing Department, The National Stock Exchange of India Ltd, Bandra Kurla Complex, Bandra (East), Mumbai 400051.  Scrip Symbol: <b>ASTERDM</b>
---	--

Dear Sir / Madam,

**Sub:**

- 1. Outcome of Board Meeting held on July 30, 2025, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**
- 2. Financial Results for the quarter ended June 30, 2025, pursuant to Regulation 33 of the Listing Regulations**

With reference to the captioned subject, we wish to inform you that:

**Unaudited financial results:**

1. The unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2025, together with the limited review report issued by M/s. Deloitte Haskins & Sells, Chartered Accounts, Statutory Auditor were reviewed by the Audit Committee, and considered & approved by the Board of Directors, at their respective meetings. The same are enclosed as **Annexure-I**.

We would like to inform that the Statutory Auditor has issued their report with an unmodified opinion on the financial results.

**17<sup>th</sup> AGM, record date for e-voting and final dividend:**

2. The 17<sup>th</sup> Annual General Meeting ("17<sup>th</sup> AGM") of the Company shall be held on Thursday, September 04, 2025, at 11.30 AM (IST) through Video Conferencing / Other Audio Visual Means.

Further to our Board meeting outcome dated May 20, 2025, wherein it was informed that the Board had inter-alia, recommended a Final Dividend of INR 1/- per equity share of INR 10/- each of the Company for the financial year 2024-25, subject to approval of Shareholders of the Company at their 17<sup>th</sup> AGM.

Accordingly, the record date for determining the eligibility of shareholders to vote on the resolutions proposed at the 17<sup>th</sup> AGM of the Company and for the payment of the Final Dividend has been fixed as Thursday, 28<sup>th</sup> August 2025.

**Amendments to policies / code:**

3. Reviewed and approved amendments to the following policies / Code:
  - i. Policy on Related Party Transactions;
  - ii. Policy for determining Materiality for Disclosures;
  - iii. Policy on Nomination, Remuneration and Evaluation;
  - iv. Code of Conduct for Prohibition of Insider Trading; and
  - v. Policy for determining Material Subsidiaries

**Transfer of assets from AMHPL to Company:**

4. Aster DM Multispecialty Hospital Private Limited ("AMHPL"), a wholly owned subsidiary of the Company had earlier entered into a lease agreement for land and building with a consortium of persons on October 06, 2023 for addition of new block (Block-D) comprising 159 beds at Aster Whitefield Hospital and the same was intimated to the stock exchanges, vide Company's letter dated October 06, 2023.

The said Block-D is currently under implementation by AMHPL and has invested in plant & machinery, IT and other infrastructure facilities to support its proposed healthcare services.

As a part of an operational and strategic need, it is proposed to transfer the assets of Block D - Aster Whitefield Hospital into the Company. Accordingly, the Board of Directors has approved the proposal to purchase the identified assets of Block D of Aster Whitefield Hospital from AMHPL at a consideration not exceeding INR 80 crores.

As part of this transaction, AMHPL will transfer the identified assets of Block D to the Company, subject to receipt of the occupancy / completion certificate and consequently, the said lease agreement will be extended in favour of the Company, granting it the right to occupy and use the land and building for its healthcare services.

The purchase of assets from AMHPL is being undertaken on arm's length basis and in the ordinary course of business. The details as required in terms of Regulation 30 of Listing Regulations, as amended, read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are annexed to this letter as **Annexure-II**.

The Meeting of the Board of Directors commenced at 11.10 AM (IST) and concluded at 04:46 P.M. (IST).

This disclosure (including copy of the amended policies / code) are being made available on the website of the Company at [www.asterdmhealthcare.in](http://www.asterdmhealthcare.in)

Kindly take the above said information on record.

Thank you.

For **Aster DM Healthcare Limited**

**Hemish Purushottam**

Company Secretary and Compliance Officer

M. No. A24331

## **INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS**

### **TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Aster DM Healthcare Limited** (the "Company"), which includes interim financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust"), for the quarter ended 30 June 2025 ("Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Unaudited Standalone Financial Results includes the interim financial information of the ESOP trust which have not been reviewed by its auditor whose interim financial information reflect total revenue of INR 0.14 crores, total net profit after tax of INR 0.12 crores and total comprehensive income of INR 0.12 crores for the quarter ended 30 June 2025, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Company.

# Deloitte Haskins & Sells

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm's Registration No. 008072S)

ANKIT  
DAGA

A red, stylized signature mark is positioned to the right of the name 'ANKIT DAGA'.

Digitally signed  
by ANKIT DAGA  
Date: 2025.07.30  
17:37:15 +05'30'

**Ankit Daga**  
Partner  
(Membership No.512486)  
(UDIN: 25512486BMOZQQ4281)

Place: Kochi  
Date: 30 July 2025

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2025**

*(Amount in INR crores)*

Particulars	Quarter ended			Year ended
	30 June 2025	31 March 2025 (refer Note 6)	30 June 2024	31 March 2025
	(Unaudited)			(Audited)
<b>1 Income</b>				
Revenue from operations	613.04	573.86	565.62	2,320.48
Other income	38.43	35.13	5,619.51	5,738.67
<b>Total income</b>	<b>651.47</b>	<b>608.99</b>	<b>6,185.13</b>	<b>8,059.15</b>
<b>2 Expenses</b>				
Purchase of medicines and medical consumables	130.46	112.80	113.12	455.49
Changes in inventories	(0.56)	3.30	(0.79)	1.82
Professional fees to consultant doctors	136.22	132.86	129.49	525.83
Laboratory outsourcing charges	17.92	16.93	17.41	73.87
Employee benefits expenses	91.48	86.06	96.22	375.09
Finance costs	21.64	23.25	21.43	85.57
Depreciation and amortisation expenses	37.88	37.76	34.64	144.52
Other expenses	104.01	107.01	108.82	431.86
<b>Total expenses</b>	<b>539.05</b>	<b>519.97</b>	<b>520.34</b>	<b>2,094.05</b>
<b>3 Profit before exceptional items and tax (1-2)</b>	<b>112.42</b>	<b>89.02</b>	<b>5,664.79</b>	<b>5,965.10</b>
<b>4 Exceptional items (refer Note 5)</b>	(4.39)	(26.42)	372.70	323.15
<b>5 Profit before tax (3+4)</b>	<b>108.03</b>	<b>62.60</b>	<b>6,037.49</b>	<b>6,288.25</b>
<b>6 Tax expenses</b>				
Current tax	28.87	12.00	21.85	74.82
Deferred tax	(1.43)	(10.47)	7.40	4.46
<b>Total tax expense</b>	<b>27.44</b>	<b>1.53</b>	<b>29.25</b>	<b>79.28</b>
<b>7 Profit for the period / year (5-6)</b>	<b>80.59</b>	<b>61.07</b>	<b>6,008.24</b>	<b>6,208.97</b>
<b>8 Other comprehensive income for the period / year</b>				
Remeasurement of net defined benefit liability	-	(1.38)	-	(1.38)
Income tax relating to items that will not be reclassified to profit or loss	-	0.35	-	0.35
<b>Other comprehensive income/(loss), net of taxes</b>	<b>-</b>	<b>(1.03)</b>	<b>-</b>	<b>(1.03)</b>
<b>9 Total comprehensive income (7+8)</b>	<b>80.59</b>	<b>60.04</b>	<b>6,008.24</b>	<b>6,207.94</b>
<b>10 Paid-up equity share capital (Face value of INR 10 each) (refer Note 4)</b>	518.13	499.52	499.52	499.52
<b>11 Other equity</b>				2,839.97
<b>12 Earnings per share (Face value of INR 10 each)</b>	Not annualised	Not annualised	Not annualised	Annualised
Basic (in INR)	1.58	1.23	120.67	124.67
Diluted (in INR)	1.57	1.22	120.50	124.52

See accompanying notes to the Statement of Unaudited Standalone Financial Results

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Notes to the statement of Unaudited Standalone Financial Results:**

- 1) The Statement of Unaudited Standalone Financial Results ('the Statement') of Aster DM Healthcare Limited ('the Company') which includes the financial information of DM Healthcare Employees Welfare Trust (the 'ESOP Trust') for the quarter ended 30 June 2025 has been reviewed by the Audit Committee on 29 July 2025 and approved by the Board of Directors on 30 July 2025. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The report of the statutory auditor is unmodified.
- 2) The Statement has been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
- 3) In accordance with Ind AS 108, Operating Segments, segment information has been provided in the Statement of Unaudited Consolidated Financial Results of the Company and therefore no separate disclosure on segment information is given in the Statement of Unaudited Standalone Financial Results.
- 4) On 15 April 2025, the Company has received the approval from the Competition Commission of India for the preferential allotment of 1,86,07,969 equity shares of INR 10 each to BCP Asia II TopCo IV Pte. Ltd and Centella Mauritius Holdings Limited, which was completed on 29 April 2025. Subsequently, the Company received an In-principle approval for listing of these shares from the National Stock Exchange of India Limited on 29 May 2025 and BSE Limited on 05 June 2025.
- 5) During the quarter ended 30 June 2025, the Company has incurred a non-recurring expense of INR 4.39 crores towards professional fees for merger and proposed acquisition. Accordingly, the same has been presented as an exceptional item in the Statement.
- 6) The figures for the quarter ended 31 March 2025 are balancing figures between the audited figures in respect of year ended 31 March 2025 and the unaudited published figures in respect of nine months ended 31 December 2024, which was subjected to limited review by the Statutory Auditors.
- 7) Statement of Unaudited Standalone Financial Results are available for perusal at the website of the Company and the stock exchanges.

*For and on behalf of the Board of Directors of*

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

MANDAYAPU Digitally signed by  
RATH AZAD MANDAYAPURATH  
MOOPEN AZAD MOOPEN  
Date: 2025.07.30  
17:12:24 +05'30'

**Dr. Azad Moopen**

*Chairman and Managing Director*

DIN 00159403

Kochi

30 July 2025

## **INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

### **TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Aster DM Healthcare Limited** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), and its share of the net loss after tax and total comprehensive loss of its associates for the quarter ended 30 June 2025 ("Statement") which includes the financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities as provided in Annexure 1.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Unaudited Consolidated Financial Results includes the interim financial information of 15 subsidiaries and ESOP trust which have not been reviewed by their auditors, whose interim financial information reflect total revenue of INR 87.09 crores, total loss after tax of INR 11.34 crores and total comprehensive loss of INR 11.34 crores for the quarter ended 30 June 2025, as considered in the Statement. The Unaudited Consolidated Financial Results also includes the Group's share of loss after tax of INR 5.72 crores and total comprehensive loss of INR 5.72 crores for the quarter ended 30 June 2025, in respect of 4 associates based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

# Deloitte Haskins & Sells

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm's Registration No. 008072S)

ANKIT  
DAGA  Digitally signed  
by ANKIT DAGA  
Date: 2025.07.30  
17:39:13 +05'30'

**Ankit Daga**  
Partner  
(Membership No. 512486)  
(UDIN: 25512486BMOZQR4168)

Place: Kochi  
Date: 30 July 2025

# Deloitte Haskins & Sells

## Annexure 1 – List of entities included in the Unaudited Consolidated Financial Results

S.No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Wholly owned Subsidiary	India
5	Sri Sainatha Multispecialty Hospitals Private Limited	Wholly owned Subsidiary	India
6	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
7	DM Healthcare Employees Welfare Trust	Wholly owned Subsidiary	India
8	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
9	Malabar Institute of Medical Sciences Limited	Subsidiary	India
10	Dr. Ramesh Cardiac and Multispecialty Hospitals Private Limited	Subsidiary	India
11	Prerana Hospital Limited	Subsidiary	India
12	Hindustan Pharma Distributors Private Limited	Subsidiary	India
13	EMED Human Resources India Private Limited	Step down Subsidiary	India
14	Ezhimala Infrastructure LLP	Step down Subsidiary	India
15	Warseps Healthcare LLP	Step down Subsidiary	India
16	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
17	Aster Ramesh Duhita LLP	Step down Subsidiary	India
18	Komali Fertility Centre LLP	Step down Subsidiary	India
19	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
20	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
21	Cantown Infra Developers LLP	Step down Subsidiary	India
22	Aasraya Healthcare LLP	Step down Subsidiary	India
23	MIMS Infrastructure and Properties Private Limited	Associate	India
24	Alfaone Medicals Private Limited	Associate	India
25	Alfaone Retail Pharmacies Private Limited	Associate	India
26	Mindriot Research and Innovation Foundation	Associate	India

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025

(Amount in INR crores)

Particulars	Quarter ended			Year ended
	30 June 2025	31 March 2025 (Refer Note 7)	30 June 2024	31 March 2025
	(Unaudited)			(Audited)
<b>Continuing operations</b>				
<b>1 Income</b>				
Revenue from operations	1,077.87	1,000.34	1,001.87	4,138.46
Other income	33.18	31.28	48.72	148.23
<b>Total income</b>	<b>1,111.05</b>	<b>1,031.62</b>	<b>1,050.59</b>	<b>4,286.69</b>
<b>2 Expenses</b>				
Purchase of medicines and medical consumables	247.15	218.17	225.29	920.16
Changes in inventories	(0.01)	7.06	3.32	18.17
Professional fees to consultant doctors	239.70	229.98	225.91	921.17
Laboratory outsourcing charges	7.76	6.99	5.60	29.21
Employee benefits expense	194.81	182.96	190.44	760.39
Finance costs	30.77	32.43	29.15	123.81
Depreciation and amortisation expenses	63.22	63.95	60.41	248.84
Other expenses	181.10	163.11	187.77	724.83
<b>Total expenses</b>	<b>964.50</b>	<b>904.65</b>	<b>927.89</b>	<b>3,746.58</b>
<b>3 Profit before share of loss of equity accounted investees, exceptional items and tax (1-2)</b>	<b>146.55</b>	<b>126.97</b>	<b>122.70</b>	<b>540.11</b>
4 Share of loss of equity accounted investees	(5.72)	(10.01)	(2.71)	(18.91)
5 Exceptional items (Refer Note 5)	(4.39)	(26.42)	-	(50.14)
<b>6 Profit before tax (3+4+5)</b>	<b>136.44</b>	<b>90.54</b>	<b>119.99</b>	<b>471.06</b>
<b>7 Tax expense</b>				
Current tax	43.98	18.01	30.43	125.73
Deferred tax	(1.10)	(13.01)	8.56	8.64
<b>Total tax expense</b>	<b>42.88</b>	<b>5.00</b>	<b>38.99</b>	<b>134.37</b>
<b>8 Profit for the period/ year from continuing operations (6-7)</b>	<b>93.56</b>	<b>85.54</b>	<b>81.00</b>	<b>336.69</b>
<b>9 Discontinued operations</b>				
(a) Loss before tax from discontinued operations (Refer Note 6)	-	-	(76.89)	(76.89)
(b) Tax expense of discontinued operations (Refer Note 6)	-	-	-	-
(c) Gain on disposal of business operations (Refer Note 6)	-	-	5,148.09	5,148.09
<b>Profit after tax from discontinued operations (a+b+c)</b>	<b>-</b>	<b>-</b>	<b>5,071.20</b>	<b>5,071.20</b>
<b>10 Profit for the period/ year (8+9)</b>	<b>93.56</b>	<b>85.54</b>	<b>5,152.20</b>	<b>5,407.89</b>
<b>11 Other comprehensive income/ (loss) for the period/ year</b>				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Remeasurement of net defined benefit liability	-	(3.09)	-	(3.09)
Income tax on items that will not be reclassified subsequently to profit or loss	-	0.79	-	0.79
<i>Items that will be reclassified subsequently to profit or loss</i>				
Exchange difference in translating financial statements of foreign operations	(0.54)	0.37	0.02	0.25
Income tax on items that will be reclassified subsequently to profit or loss	0.14	(0.06)	-	(0.06)
<b>Other comprehensive income/ (loss), net of taxes</b>	<b>(0.40)</b>	<b>(1.99)</b>	<b>0.02</b>	<b>(2.11)</b>
<b>12 Total comprehensive income (10+11)</b>	<b>93.16</b>	<b>83.55</b>	<b>5,152.22</b>	<b>5,405.78</b>
<b>13 Profit attributable to :</b>				
Owners of the Company	85.52	79.02	5,145.18	5,377.83
Non-controlling interests	8.04	6.52	7.02	30.06
<b>Profit for the period/ year</b>	<b>93.56</b>	<b>85.54</b>	<b>5,152.20</b>	<b>5,407.89</b>
<b>14 Other comprehensive income/ (loss) attributable to :</b>				
Owners of the Company	(0.40)	(1.92)	0.02	(2.04)
Non-controlling interests	-	(0.07)	-	(0.07)
<b>Other comprehensive income/ (loss) for the period/ year</b>	<b>(0.40)</b>	<b>(1.99)</b>	<b>0.02</b>	<b>(2.11)</b>
<b>15 Total comprehensive income attributable to :</b>				
Owners of the Company	85.12	77.10	5,145.20	5,375.79
Non-controlling interests	8.04	6.45	7.02	29.99
<b>Total comprehensive income for the period/ year</b>	<b>93.16</b>	<b>83.55</b>	<b>5,152.22</b>	<b>5,405.78</b>
<b>16 Paid-up equity share capital (Face value of INR 10 each) (Refer Note 4)</b>	<b>518.13</b>	<b>499.52</b>	<b>499.52</b>	<b>499.52</b>
<b>17 Other equity</b>				<b>2,928.55</b>
<b>18 Earnings per share (Face value of INR 10 each) from</b>				
<b>Continuing Operations (INR)</b>				
Basic	1.67	1.59	1.49	6.16
Diluted	1.67	1.58	1.48	6.15
<b>Discontinued Operations (INR)</b>				
Basic	-	-	101.85	101.82
Diluted	-	-	101.71	101.70
<b>Continuing &amp; Discontinued Operations (INR)</b>				
Basic	1.67	1.59	103.34	107.98
Diluted	1.67	1.58	103.19	107.85

See accompanying notes to the Statement of Unaudited Consolidated Financial Results

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Segment details of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025**

(Amount in INR crores)

Particulars	Quarter ended			Year ended
	30 June 2025	31 March 2025 (Refer Note 7)	30 June 2024*	31 March 2025*
	(Unaudited)			(Audited)
<b>1 Segment revenue</b>				
Hospitals	1,046.95	970.83	1,004.14	4,029.90
Clinics	7.26	9.40	30.36	57.79
Wholesale Pharmacies*	20.61	17.65	49.22	126.72
Others	3.05	2.46	2.03	7.93
<b>Total</b>	<b>1,077.87</b>	<b>1,000.34</b>	<b>1,085.75</b>	<b>4,222.34</b>
<b>2 Segment results before tax, exceptional items and finance cost</b>				
Hospitals	185.32	156.54	150.16	686.40
Clinics	(2.18)	(1.09)	(0.29)	(5.33)
Wholesale Pharmacies*	(8.61)	(8.75)	(7.61)	(33.53)
Others	(5.99)	(7.40)	(4.86)	(24.16)
<b>Total</b>	<b>168.54</b>	<b>139.30</b>	<b>137.40</b>	<b>623.38</b>
<b>Adjustment :</b>				
Finance cost	(30.77)	(32.43)	(32.30)	(126.96)
Share of loss of equity accounted investees	(5.72)	(10.01)	(2.71)	(18.91)
Other unallocable expenditure net of unallocable income (including adjustment of exceptional items)	4.39	(6.32)	(59.29)	(83.34)
Gain on disposal of business operations	-	-	5,148.09	5,148.09
<b>Profit before tax from Continuing and Discontinued Operations</b>	<b>136.44</b>	<b>90.54</b>	<b>5,191.19</b>	<b>5,542.26</b>
<b>3 Segment assets</b>				
Hospitals**	6,223.58	5,013.66	4,583.34	5,013.66
Clinics	17.14	48.55	12.19	48.55
Wholesale Pharmacies*	56.06	52.84	62.78	52.84
Others	25.00	34.41	31.45	34.41
Unallocated	1,465.98	1,456.92	1,753.19	1,456.92
<b>Total</b>	<b>7,787.76</b>	<b>6,606.38</b>	<b>6,442.95</b>	<b>6,606.38</b>
<b>4 Segment liabilities</b>				
Hospitals	2,898.04	2,759.47	2,453.17	2,759.47
Clinics	10.68	10.40	29.77	10.40
Wholesale Pharmacies*	27.89	23.51	33.04	23.51
Unallocated	150.95	161.55	332.21	161.55
<b>Total</b>	<b>3,087.56</b>	<b>2,954.93</b>	<b>2,848.19</b>	<b>2,954.93</b>

\* includes retail pharmacies and opticals of Gulf Cooperation Council (GCC) business

\*\* includes investment made in Quality Care India Limited during the quarter ending 30 June 2025

See accompanying notes to the Statement of Unaudited Consolidated Financial Results

**Notes to the Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025:**

- The Statement of Unaudited Consolidated Financial Results ('the Statement') of Aster DM Healthcare Limited ('the Parent Company') and its subsidiaries (together referred to as 'the Group'), DM Healthcare Employees Welfare Trust (the 'ESOP Trust') and its share of loss in associates for the quarter ended 30 June 2025 has been reviewed by the Audit Committee on 29 July 2025 and approved by the Board of Directors 30 July 2025. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Parent Company. The report of the statutory auditor is unmodified.
- The Statement has been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
- On 06 May 2025, the Group entered into an agreement to lease for a composite property located at Sarjapur Road, Bengaluru, Karnataka, to establish its fourth multispecialty hospital in the city.
- On 15 April 2025, the Parent Company has received the approval from the Competition Commission of India for the preferential allotment of 1,86,07,969 equity shares of INR 10 each to BCP Asia II TopCo IV Pte. Ltd and Centella Mauritius Holdings Limited, which was completed on 29 April 2025. Subsequently, the Parent Company received an In-principle approval for listing of these shares from the National Stock Exchange of India Limited on 29 May 2025 and BSE Limited on 05 June 2025.
- During the quarter ended 30 June 2025, the Parent Company has incurred a non-recurring expense of INR 4.39 crores towards professional fees for merger and a proposed acquisition. Accordingly, the same has been presented as an exceptional item in the Statement.

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangirannagar, Bangalore, Karnataka, India, 560027

- 6) During the previous financial year, the Group announced the completion of the separation of its Gulf Cooperation Council ('GCC') business. As a result, the Group classified the GCC business as Discontinued Operations in the Statement.

Discontinued Operations include direct expenses, including transaction cost, clearly identifiable to the businesses being discontinued.

The impact of discontinued operations on income, expenses and tax is as under:

*(Amount in INR crores)*

Particulars	Quarter ended			Year ended
	30 June 2025	31 March 2025 (Refer Note 7)	30 June 2024	31 March 2025
	(Unaudited)			(Audited)
<b>Income</b>				
Revenue from operations	-	-	83.88	83.88
<b>Total income</b>	-	-	<b>83.88</b>	<b>83.88</b>
<b>Expenses</b>				
Purchase of medicines and medical consumables	-	-	26.65	26.65
Professional fees to consultant doctors	-	-	11.61	11.61
Employee benefits expense	-	-	40.41	40.41
Finance costs	-	-	3.15	3.15
Depreciation and amortisation expenses	-	-	5.84	5.84
Other expenses	-	-	73.11	73.11
<b>Total expenses</b>	-	-	<b>160.77</b>	<b>160.77</b>
<b>Loss before tax</b>	-	-	<b>(76.89)</b>	<b>(76.89)</b>
<b>Tax expense</b>				
Current tax	-	-	-	-
Deferred tax	-	-	-	-
<b>Total tax expense</b>	-	-	-	-
<b>Loss for the period/ year from discontinued operations</b>	-	-	<b>(76.89)</b>	<b>(76.89)</b>
<b>Gain on disposal of business operations</b>	-	-	<b>5,148.09</b>	<b>5,148.09</b>
<b>Profit after tax from discontinued operations</b>	-	-	<b>5,071.20</b>	<b>5,071.20</b>

- 7) The figures for the quarter ended 31 March 2025 are balancing figures between the audited figures in respect of year ended 31 March 2025 and the unaudited published figures in respect of nine months ended 31 December 2024, which was subjected to limited review by the Statutory Auditors.
- 8) Statements of Standalone and Consolidated Financial Results are available for perusal at the website of the Parent Company and the stock exchanges.

*For and on behalf of the Board of Directors of*

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

MANDAYAPU

RATH AZAD

MOOPEN

**Dr. Azad Moopen**

*Chairman and Managing Director*

DIN 00159403

Kochi

30 July 2025

Digitally signed by  
MANDAYAPURATH  
AZAD MOOPEN  
Date: 2025.07.30  
17:13:54 +05'30'

**Aster DM Healthcare Limited**  
CIN : L85110KA2008PLC147259

Registered office : Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangiramnagar, Bangalore, Karnataka, India, 560027

**Annexure A to statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025**

Sl No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Wholly owned Subsidiary	India
5	Sri Sainatha Multispecialty Hospitals Private Limited	Wholly owned Subsidiary	India
6	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
7	DM Healthcare Employees Welfare Trust	Trust	India
8	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
9	Malabar Institute of Medical Sciences Limited	Subsidiary	India
10	Dr. Ramesh Cardiac and Multispecialty Hospitals Private Limited	Subsidiary	India
11	Prerana Hospital Limited	Subsidiary	India
12	Hindustan Pharma Distributors Private Limited	Subsidiary	India
13	EMED Human Resources India Private Limited	Step down Subsidiary	India
14	Ezhimala Infrastructure LLP	Step down Subsidiary	India
15	Warseps Healthcare LLP	Step down Subsidiary	India
16	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
17	Aster Ramesh Duhita LLP	Step down Subsidiary	India
18	Komali Fertility Centre LLP	Step down Subsidiary	India
19	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
20	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
21	Cantown Infra Developers LLP	Step down Subsidiary	India
22	Aasraya Healthcare LLP	Step down Subsidiary	India
23	MIMS Infrastructure and Properties Private Limited	Associate	India
24	Alfaone Medicals Private Limited	Associate	India
25	Alfaone Retail Pharmacies Private Limited	Associate	India
26	Mindriot Research and Innovation Foundation	Associate	India

**Annexure-II**

**Disclosure under sub-para (5) of Para B of Part A of Schedule III of Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

Sr. No	Particulars	Details
1	name(s) of parties with whom the agreement is entered;	Originally, Aster DM Healthcare (Trivandrum) Private Limited ("AMHPL"), a Wholly Owned Subsidiary ("WOS") of the Company has entered into a lease agreement dated October 06, 2023, with Association of Persons. The lease agreement will now be extended to the Company. Transfer of identified assets of Block D from AMHPL to the Company.
2	purpose of entering into the agreement;	Originally entered for addition of new block of 159 beds by AMHPL for Aster Whitefield Hospital with estimated capacity increase in capacity from 347 beds to 506 beds.  As a part of an operational and strategic need, it is proposed to transfer the assets of Block D - Aster Whitefield Hospital into the Company. Accordingly, the Board of Directors has approved the proposal to purchase the identified assets of Block D of Aster Whitefield Hospital from AMHPL at a consideration not exceeding INR 80 crores, subject to receipt of the occupancy / completion certificate.  As part of this transaction and in accordance with the terms of the said agreement, the lease agreement will be extended to the Company.
3	size of agreement;	The original lease, effective from October 06, 2023, has a tenure of 30 years and will continue with the Company with a lock-in period of 30 years from Lessor and 15 years for the Lessee.
4	Shareholding, if any, in the entity with whom the agreement is executed;	AMHPL is a Wholly Owned Subsidiary of the Company. Except for this, the Company does not have any shareholding in any of the proposed lessors. NIL
5	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	Not applicable.

Sr. No	Particulars	Details
6	whether, the said parties are related to promoter / promoter group / group companies in any manner. If yes, nature of relationship;	No
7	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length	The proposed transfer of assets between the Company and AMHPL constitutes a Related Party Transaction. The transaction is being undertaken on an arm's length basis.  The lease agreement which is being extended to the Company is not entered into with the related parties.
8	in case of issuance of shares to the parties, details of issue price, class of shares issued;	Not applicable.
9	in case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	Not applicable.
10	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	Extension of lease agreement is being entered into with a third party and there is no conflict of interest. There is no right to nominees on the Board of Directors of the Company.  Purchase of identified assets is from AMHPL, a WOS of the Company.
11	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):  i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof.	Not applicable.